Alpha Cognition Soars in Q4: Commercial Launch Progress and Payer Access Drive Growth
In a major milestone, Alpha Cognition has reported continued sales growth and ongoing demand expansion of its flagship product, ZUNVEYL, which is the first new oral Alzheimer's treatment approved in more than 15 years. According to Michael McFadden, Chief Executive Officer of Alpha Cognition, the company's commercial launch progress has been marked by further traction in long-term care, including expanding both breadth and depth of prescribing in the $2 billion high-volume long-term care market.
One notable highlight from the quarter is the progress made on payer access. The company announced that it has secured a second signed contract with a national PBM, bringing its total contracted coverage to two out of the top four PBMs nationwide. This development is expected to drive further growth and expansion of ZUNVEYL's reach in the market.
Furthermore, Alpha Cognition has maintained a strong financial foundation, which enables the company to remain well-funded with a clear path toward operational profitability in 2027. The company raised $40 million in Q3, which allowed it to appropriately expand its commercial reach and payer engagement strategies.
In addition to these solid commercial and operational progress, Alpha Cognition has announced three real-world studies that are or will be initiated in 2026. These studies will provide further evidence to strengthen ZUNVEYL's positioning with payers and provide additional evidence for healthcare providers who need a therapy that's well-tolerated and demonstrates behavioral and cognitive efficacy for their patients.
According to Lauren D'Angelo, Chief Operating Officer of Alpha Cognition, the company's commercial strategy is progressing well, driven by expanding payer access and increasing demand in long-term care. As the market leader in this space, Alpha Cognition remains committed to delivering innovative solutions that meet the evolving needs of patients with Alzheimer's disease.
The success of ZUNVEYL has been significant, marking a major milestone for the company and the field of Alzheimer's treatment. With continued growth and expansion expected in 2026 and beyond, investors are closely watching Alpha Cognition as it continues to drive innovation and progress in this critical space.
